Literature DB >> 20651774

Evidence summary: what 'cost of illness' evidence is there about cross-infection related infections in dental practice?

Chris Fox1.   

Abstract

Since August 2009, members of the Primary Care Dentistry Research Forum (http://www.dentistryresearch.org) have taken part in an online vote to identify questions in day-to-day practice that they felt most needed to be answered with conclusive research. The question which receives the most votes each month forms the subject of a critical appraisal of the relevant literature. Each month a new round of voting takes place to decide which further questions will be reviewed. Dental practitioners and dental care professionals are encouraged to take part in the voting and submit their own questions to be included in the vote by joining the website.The paper below details a summary of the findings of the seventh critical appraisal. In conclusion, the critical appraisal identified no evidence on the epidemiological scale of cross-infection caused in dental practices and therefore also of the cost impact of cross-infection caused in primary dental practices. As a result, no 'cost of illness', or cost-benefit assessment, exists or is feasible at this time.

Entities:  

Mesh:

Year:  2010        PMID: 20651774     DOI: 10.1038/sj.bdj.2010.651

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  3 in total

1.  Evidence-based dentistry--overcoming the challenges for the UK's dental practitioners.

Authors:  C Fox; E J Kay; R Anderson
Journal:  Br Dent J       Date:  2014-08       Impact factor: 1.626

2.  Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases.

Authors:  Sumanth Kumbargere Nagraj; Prashanti Eachempati; Martha Paisi; Mona Nasser; Gowri Sivaramakrishnan; Jos H Verbeek
Journal:  Cochrane Database Syst Rev       Date:  2020-10-12

3.  Do exposures to aerosols pose a risk to dental professionals?

Authors:  J Kobza; J S Pastuszka; E Bragoszewska
Journal:  Occup Med (Lond)       Date:  2018-09-13       Impact factor: 1.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.